Literature DB >> 32830263

Idiopathic multicentric Castleman disease with novel heterozygous Ile729Met mutation in exon 10 of familial Mediterranean fever gene.

Yushiro Endo1, Tomohiro Koga1, Hiroki Otaki2, Daisuke Sasaki3, Remi Sumiyoshi1, Kaori Furukawa1, Yoshimasa Tanaka2, Yanagihara Katsunori3, Atsushi Kawakami1.   

Abstract

OBJECTIVE: While the aetiology of idiopathic multicentric Castleman disease (iMCD) remains unclear, the involvement of autoinflammatory mechanisms has been suggested. Herein we report a Japanese patient with iMCD with a novel heterozygous Ile729Met mutation in exon 10 of the Mediterranean fever (MEFV) gene.
METHODS: We performed genetic analysis via targeted next-generation sequencing analysis and Sanger sequencing and conducted molecular dynamics simulations to investigate the hydrophobic interactions around the 729th amino acid in human pyrin.
RESULTS: In February 2011, a 59-year-old man was diagnosed with IgG4-related disease at our department based on the findings of cervical and hilar lymphadenopathies, typical lung lesions and cervical lymph node biopsy. The patient was followed up without treatment, as he was asymptomatic. However, he had been experiencing prolonged fatigue and fever with high levels of CRP since June 2017. Axillary lymph node biopsy findings led to the diagnosis of iMCD. He was successfully treated with an IL-6 inhibitor and has been in remission for 12 months. Genetic analyses for hereditary autoinflammatory disease-related genes were performed, revealing a novel heterozygous Ile729Met mutation in exon 10 of the MEFV gene. We identified that this novel mutation significantly altered the local interaction of the human pyrin B30.2 domain by molecular dynamics simulation analysis and experimentally had the potential for inflammasome activation with increased inflammatory cytokines.
CONCLUSION: The abnormal function of pyrin due to a mutation in the MEFV gene in this patient may have contributed to the development of MCD by inducing IL-6 production via inflammasome signalling.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Castleman disease; MEFV; molecular dynamics simulations; novel mutation; pyrin

Mesh:

Substances:

Year:  2021        PMID: 32830263     DOI: 10.1093/rheumatology/keaa269

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  4 in total

1.  Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.

Authors:  Wanying Liu; Qingqing Cai; Tiantian Yu; Paolo Strati; Frederick B Hagemeister; Qiongli Zhai; Mingzhi Zhang; Ling Li; Xiaosheng Fang; Jianyong Li; Ruifang Sun; Shanxiang Zhang; Hanjin Yang; Zhaoming Wang; Wenbian Qian; Noriko Iwaki; Yasuharu Sato; Eric Oksenhendler; Zijun Y Xu-Monette; Ken H Young; Li Yu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

Review 2.  Castleman disease.

Authors:  Antonino Carbone; Margaret Borok; Blossom Damania; Annunziata Gloghini; Mark N Polizzotto; Raj K Jayanthan; David C Fajgenbaum; Mark Bower
Journal:  Nat Rev Dis Primers       Date:  2021-11-25       Impact factor: 65.038

3.  Candidate biomarkers for idiopathic multicentric Castleman disease.

Authors:  Remi Sumiyoshi; Tomohiro Koga; Atsushi Kawakami
Journal:  J Clin Exp Hematop       Date:  2022

4.  Mediterranean fever gene variants modify clinical phenotypes of idiopathic multi-centric Castleman disease.

Authors:  Yushiro Endo; Tomohiro Koga; Yoshihumi Ubara; Remi Sumiyoshi; Kaori Furukawa; Atsushi Kawakami
Journal:  Clin Exp Immunol       Date:  2021-07-26       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.